AOD9604 is a synthetic research peptide derived from the C-terminal fragment of human growth hormone (hGH 176-191), modified with an additional stabilizing tyrosine residue. It's studied in preclinical and early clinical research for its role in lipolysis — fat breakdown — without engaging the growth-promoting or IGF-1-elevating effects associated with full-length hGH. Originally developed by the Australian biotech Metabolic Pharmaceuticals Ltd, AOD9604 progressed through six Phase I/II human trials before its pivotal efficacy trial fell short, ending formal drug development in 2007. It remains a compound of interest in metabolic and adipocyte research today. Helix Bio supplies AOD9604 as a lyophilized powder intended strictly for laboratory research, manufactured to a high-purity standard and backed by third-party verification. It is not intended for human consumption, diagnostic use, or any therapeutic application.
HPLC certified
Independent analysis
Highest standard
Full traceability
AOD9604 is studied as a modified fragment of the lipolytic domain of human growth hormone, corresponding to amino acids 176-191 (sometimes referenced as 177-191) with a tyrosine added at the N-terminus for stability. The idea behind the molecule was to isolate hGH's fat-metabolism activity from its growth-promoting and blood-sugar-affecting properties, since those effects are what limit full-length hGH's use in metabolic research and complicate its interpretation. Preclinical work in rodent and adipose tissue models found that AOD9604 does not raise IGF-1 levels or impair glucose tolerance the way full-length hGH does, which is the main reason it's treated as a distinct research tool rather than a hGH substitute.
Helix Bio's AOD9604 is supplied as a lyophilized (freeze-dried) powder — a synthetic 16-amino-acid peptide manufactured under controlled laboratory conditions. Lyophilization extends shelf stability prior to reconstitution, which is useful for labs running studies over an extended timeline rather than using a full vial at once.
This product exists to support in vitro and preclinical laboratory research only. It's manufactured, labeled, and sold for research use only (RUO) — not for human or veterinary use, not for diagnostic procedures, and not for compounding. It's intended for researchers studying lipolysis, adipocyte metabolism, fat oxidation pathways, or the pharmacology of growth-hormone-derived peptide fragments.
AOD9604 has a research history that's a little different from most peptides on the market — it actually went through a formal pharmaceutical development program, with published safety data from real human trials, before that program was discontinued for efficacy reasons rather than safety ones. That gives researchers a documented starting point most experimental peptides don't have. Helix Bio manufactures its AOD9604 domestically, backs every batch with purity testing, and issues documentation so researchers can evaluate what they're working with before it reaches the bench. If your protocol calls for a well-characterized hGH-fragment peptide for lipolysis or adipocyte research, that's what this listing is built around.
This product is not intended for individual consumers seeking to use it outside a research setting.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Cyclic peptides resist protease degradation and reach undruggable targets. Learn how peptide cyclization works and why stability improves. Explore the research.
How continuous flow, automation, enzymatic routes and AI are changing peptide synthesis technology, and what it means for research peptide purity and supply.
AI now designs peptides from scratch. How AlphaFold 3, RFdiffusion and protein language models reshaped peptide discovery in 2026 — research use only.
